OxiracetamvsPanax Ginseng

Oxiracetam enhances glutamatergic neurotransmission through positive allosteric modulation of AMPA receptors, increasing the amplitude and duration of excitatory postsynaptic potentials. It increases the release of excitatory neurotransmitters glutamate and D-aspartic acid from hippocampal presynaptic terminals, acting as a glutamate analog. Oxiracetam stimulates protein kinase C (PKC) isoforms, particularly PKC-α and PKC-γ, which phosphorylate substrates involved in memory consolidation, long-term potentiation (LTP), and synaptic plasticity. PKC activation enhances NMDA receptor function and AMPA receptor trafficking to the synapse. Its mild stimulatory effect derives from cholinergic system enhancement via increased acetylcholine release and nicotinic α7 receptor potentiation in the cortex.

Ginsenosides (Rb1, Rg1, Rg3, Re, and others) have diverse pharmacological actions. They modulate the hypothalamic-pituitary-adrenal (HPA) axis, reducing cortisol release under stress through glucocorticoid receptor modulation. Ginsenosides inhibit acetylcholinesterase (AChE), increasing acetylcholine levels in the hippocampus and enhancing muscarinic and nicotinic receptor function. They enhance nitric oxide production via endothelial nitric oxide synthase (eNOS) for cerebral vasodilation. Rb1 and Rg1 promote BDNF and NGF expression through activation of CREB and TrkB/TrkA signaling, supporting neuroplasticity. Rg1 specifically enhances hippocampal neurogenesis via the PI3K/Akt pathway and Wnt/β-catenin signaling, and improves spatial learning in animal models. Ginsenosides may also modulate GABA-A receptors and have antioxidant properties.